tbuckley/cabot-search huggingface dataset:
Reply
Authors: Jonggi Choi, Roongruedee Chaiteerakij, Lewis R. Roberts
Journal: Hepatology (2016)

Potential conflict of interest: Dr. Roberts advises for and received grants from Wako. He consults for Axis and Medscape. He advisesfor Bayer. He received grants from Ariad, BTG, and Gilead. REPLY: We thank Altaii et al. for their interest in our article "Aspirin use and the risk of cholangiocarcinoma."1 They used a large clinical registry for external validation of the main findings of our article, which also showed an association between aspirin use and a lower risk of cholangiocarcinoma (CCA). This result provides additional supporting evidence for the potential role of aspirin for chemoprevention of CCA. However, the result should be interpreted with caution. Large databases, such as the clinical registry the authors used, may have provided a robust validation of the association between aspirin and the risk of CCA; however, as pointed out by Bagante et al.,2 these analyses may still suffer from a lack of detailed information on the dose and duration of aspirin use, as well as from confounding due to concomitant administration of nonsteroidal anti‐inflammatory drugs, which were already described as limitations of our article. Although our study used several sensitivity analyses to overcome this limitation, this issue may still be pertinent to the work of Altaii et al. In 2015, the U.S. Preventive Services Task Force recommended aspirin as the first pharmacological agent for chemoprevention of cancer in a population not characterized as high risk. Recently, Cao et al. reported on the population‐wide impact of aspirin use and the risk for cancer, showing a lower overall risk for cancer (relative risk [RR], 0.97), more particularly, gastrointestinal tract cancer (RR, 0.85), in regular aspirin users.3 Although Cao et al.'s study did not investigate CCA separately, this study provides accumulating evidence for the role of aspirin in preventing cancers, particularly cancers such as CCA which have strong associations with inflammatory conditions, such as primary sclerosing cholangitis (PSC) and biliary stone disease. Ideally, additional confirmatory evidence from a prospective, randomized trial of aspirin use for chemoprevention of CCA would provide the most robust evidence. However, as we mentioned in our article, because of the relatively low incidence of CCA, a prospective, randomized control might not be feasible for practical reasons, such as the longer follow‐up period needed, and the large number of participants needed to detect a sufficiently large effect size to demonstrate a clinically meaningful chemopreventive effect of aspirin for CCA. Nevertheless, it may be possible to perform a prospective, randomized trial in individuals who are at high risk of developing CCA, for example, those with PSC. Furthermore, recent advances in cancer genetics, genomics, and biomarkers raise the possibility that the use of aspirin for cancer prevention may be personalizable to the specific individuals most likely to benefit from the use of aspirin chemoprevention.
Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML
Authors: Youngil Koh, Dae-Young Kim, Hyuk-Chan Kwon, Min Kyoung Kim, Byung-Soo Kim, Yu-Kyung Kim, Inho Kim, Jae Seog Kim, Jin Seog Kim, Chul Soo Kim, Hyeoung-Joon Kim, Jae-Yong Kwak, Na-Ri Lee, Yoo-Hong Min, Chong Won Park, Sang Kyun Sohn, Ho-Jin Shin, Suk Joong Oh, Sung-Soo Yoon, Jung-Hee Lee, Dae Young Zang, Jooseop Chung, Jun-Won Cheong, Chul W. Jung, Deog-Yeon Jo, Yeun-Jun Chung, Seung-Hyun Jung, Hai-Dong Xu, Hyang-Min Byun, Allen S. Yang, Seonyang Park
Journal: Blood (2008)
Megakaryocytes Package and Deliver Golgi-Associated Glycosyltransferases into Platelets and to Platelet Surfaces Using Dense Granules.
Authors: Hans H. Wandall, Anne Louise Sørensen, Sunita Patel, Jennifer Richardson, Joseph E. Italiano, Victoria Rumjantseva, Eric P. Bennett, Henrik Clausen, Thomas P. Stossel, John H. Hartwig
Journal: Blood (2005)
Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.
Authors: Corinne Haioun, Nicolas Mounier, Jean François Emile, Pierre Feugier, Bertrand Coiffier, Hervé Tilly, Christian Recher, Christophe Fermé, Jean Gabarre, Raoul Herbrecht, Frank Morschhauser12, Christian Gisselbrecht
Journal: Blood (2005)
Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients.
Authors: Kolja Eppert, Katsuto Takenaka, Björn Nilsson, Eric R Lechman, Vicki Ling, Joseph Beyene, Angelo J Canty, Jayne S Danska, Mark D Minden, Todd R. Golub, Benjamin L Ebert, John E Dick
Journal: Blood (2009)
The Calcineurin/NFAT Signaling Pathway Is a Target for the Collagen Type I-Induced Calcium Response in Megakaryocytes and Mediates Expression of Megakaryocytic Genes.
Authors: Satu Kyttaelae, Ivonne Habermann, Martin Bornhaeuser, Gerhard Ehninger, Alexander Kiani
Journal: Blood (2007)
Lumen-apposing metal stents for pancreatic fluid collection drainage: may not be business as usual?
Authors: John S Leeds, Manu K Nayar, Richard M Charnley, Kofi W Oppong
Journal: Gut (2016)

We read with interest the paper by Bang et al 1 concerning their interim analysis of an ongoing randomised study comparing a novel fully covered self-expanding metal stent (fcSEMS) to plastic stents in patients undergoing endoscopic drainage of walled-off pancreatic necrosis (WOPN). This was following concerns over higher than expected adverse events in the fcSEMS (50%) compared with the plastic stent group (0%). Specifically, these adverse events were three cases of bleeding, two cases of buried stent and one case of biliary stricture. The three cases of bleeding were found to have pseudoaneurysms, which were treated by radiologically guided coiling. One of the buried stent cases developed severe bleeding on removal and requiring radiological intervention. The biliary stricture was managed endoscopically with fcSEMS removal and biliary …
Phenotype is king, researchers say, after 20 family members have condition misdiagnosed
Authors: Michael McCarthy
Journal: BMJ (2016)

More than 20 members of a family wrongly had a lethal heart rhythm condition diagnosed after incorrect application and interpretation of genetic tests, investigators have reported in a study published in Mayo Clinic Proceedings .1 They say that this demonstrates the hazards of genetic testing when used inappropriately and interpreted incorrectly.

The case involved a Hispanic family whose son had died suddenly in his sleep at age 13. At autopsy the boy’s heart was found to be enlarged and had several abnormalities including fibrillar disarray in the left ventricle, diffuse areas of fibrosis in the papillary muscles, and marked endocardial fibrosis in the left atrium, but the medical examiner deemed the autopsy inconclusive for a specific cardiomyopathy.

After the boy’s death his parents and brother underwent cardiological testing and were initially found to be normal. …
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer
Authors: Lan Lu, Zhi Jie Li, Long Fei Li, William Ka Kei Wu, Jing Shen, Lin Zhang, Ruby Lok Yi Chan, Le Yu, Ya Wei Liu, Shun Xiang Ren, Kam Ming Chan, Chi Hin Cho
Journal: Journal of Controlled Release (2015)
DDEL-04AshwaMAX AND WITHAFERIN A INHIBITS GLIOMAS IN CELLULAR AND MURINE ORTHOTOPIC MODELS
Authors: Edwin Chang, Christoph Pohling, Arutselvan Natarajan, Timothy Witney, Jasdeep Kaur, Lingyun Xu, Gayatri Gowrishankar, Aloma de Souza, Sophie Schick, Liyin Chan, Nicholas Wu, Phoo Khaw, Paul Mischel, Taher Abbasi, Shahabuddin Usmani, Parag Mallick, Sanjiv S. Gambhir
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma multiforme (GBM) is an aggressive, malignant cancer. An extract from the winter cherry plant (Withania somnifera), AshwaMAX, is concentrated (4.3%) for Withaferin A, a steroidal lactone that inhibits cancer cells. We hypothesized that AshwaMAX could treat GBM and that bioluminescent molecular imaging (BLI) could track oral therapy in orthotopic murine models of glioblastoma. METHODS: Human glioblastoma cells (GBM2, GBM39) were isolated from primary tumors while U87-MG was obtained commercially. Proliferative potential of these cells was assessed by the alamar blue bioassay. GBM2 was transduced with lentiviral vectors that express GFP/firefly luciferase fusion proteins. Mutational, expression and proliferative status of GBMs were studied. Intracranial xenografts of glioblastomas were grown in the right parietal regions of female, nude mice (n = 3-5 per experiment). Tumor growth was followed through BLI. RESULTS: Both wild type and EGFRvIII were present in GBM2 and GBM39. GBM39 expressed EGFRvIII 20-fold higher than GBM2 but U87-MG had virtually no EGFRvIII. Neurosphere cultures of U87-MG, GBM2 and GBM39 were inhibited by AshwaMAX at IC50 of 1.4, 0.19 and 0.22 µM equivalent respectively and by Withaferin A with IC50 of 0.31, 0.28 and 0.25 µM respectively. These data led to preclinical studies with pcGBM2 xenografts in nude mice. Oral gavage, every other day, of non-toxic doses of AshwaMAX (40mg/kg per day) significantly reduced bioluminescence signal (n = 3 mice, p < 0.02, four parameter non-linear regression analysis). After 30 days, bioluminescent signal increased suggesting the onset of resistance. BLI signal for control, untreated mice increased and then plateaued. Similar findings were reported for GBM39/luc xenografts. BLI microscopy showed diffuse growth patterns of GBM2 in murine brain. CONCLUSION: With AshwaMAX, GBM neurospheres collapsed at nanomolar concentrations. Pioneering preclinical studies confirmed that AshwaMAX is effective against GBM in orthotopic murine models. AshwaMAX is thus a promising candidate for future clinical translation in GBM.
Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)
Authors: Alan F List, Maria R Baer, David Steensma, Azra Raza, Jason Esposito, Jodi Virkus, Carole Paley, John Feigert, Emmanuel C Besa
Journal: Blood (2008)
18F-Florbetaben
Authors: Emmanuel D’Estanque, Benjamin Chambert, Olivier Moranne, Pierre Olivier Kotzki, Vincent Boudousq
Journal: Clinical Nuclear Medicine (2016)

We report the case of a 73-year-old man with a documented (renal biopsy) light-chain amyloidosis (AL) imaged with 18F-AV-1 (18F-florbetaben) compared with a volunteer. A cardiac amyloidosis was suspected. As it was an AL and not a transthyretin amyloidosis, 18F-FDG and 18F-florbetaben PET/CT were preferred to bone scan. 18F-FDG scintigraphy showed a focal cardiac hypermetabolism. In addition of the heart, 18F-florbetaben scintigraphy showed an intense spleen and thyroid pathologic uptake and a moderate salivary gland and kidney uptake. 18F-florbetaben PET/CT appears to be useful for staging systemic amyloidosis.
Unrelated Donor Marrow Transplantation for Acute Lymphoblastic Leukemia in Japan. A Japan Marrow Donor Program Experience between 1993 and 2003.
Authors: Masahiro Tsuchida, Hiroshi Sao, Hisashi Sakamaki, Keisei Kawa, Yoshinobu Kanda, Koji Kato, Masamichi Hara, Mutsuo Ishii, Akira Kikuchi, Jun Okamura, Atsuo Maruta, Yoichi Takaue, Masaharu Kasai, Hiromasa Yabe, Yasuo Morishima, Shunichi Kato, Yoshihisa Kodera
Journal: Blood (2005)
Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays.
Authors: Cafer Adiguzel, Omer Iqbal, Michael Sammikannu, Josephine Cunanan, Walter Jeske, Debra Hoppensteadt, Jawed Fareed
Journal: Blood (2007)
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation
Authors: Daniel Fuerst, Christine Neuchel, Dietger Niederwieser, Donald Bunjes, Martin Gramatzki, Eva Wagner, Gerald Wulf, Bertram Glass, Michael Pfreundschuh, Hermann Einsele, Renate Arnold, Gernot Stuhler, Kerstin Schaefer-Eckart, Sebastian Freitag, Jochen Casper, Martin Kaufmann, Mohammed Wattad, Bernd Hertenstein, Stefan Klein, Mark Ringhoffer, Daphne Mytilineos, Chrysanthi Tsamadou, Carlheinz Mueller, Hubert Schrezenmeier, Joannis Mytilineos
Journal: Blood (2016)
A New Disulfide-Linked Dimer of a Single-Chain Antibody Fragment Against Human CD47 Induces Apoptosis in Lymphoid Malignant Cells In Vitro and In Vivo Via the HIF-1α Pathway: A Possible Novel Therapeutic Agent for B-CLL.
Authors: Morihiko Sagawa, Takatsune Shimizu, Mingji Xian, Aki Chizuka, Naoshi Fukushima, Yasuko Kinoshita, Iwao Ohizumi, Yasuo Ikeda, Hisafumi Okabe, Masahiro Kizaki
Journal: Blood (2006)
Durable Remission with Decreased HTLV-I Proviral Load after Reduced-Intensity Stem Cell Transplantation (RIST) in Patients with Adult T-Cell Leukemia/Lymphoma (ATL).
Authors: Ryuji Tanosaki, Kisato Nosaka, Shin Mineishi, Shin-ichiro Mori, Sung-Won Kim, Masahiro Kami, Mari Kannagi, Shunro Sonoda, Jun Okamura, Takahiro Fukuda, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2005)
Who Belongs in the Cardiac Intensive Care Unit?
Authors: Jason N. Katz
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
CD34 Expression in Adult Acute Lymphoblastic Leukemia (ALL) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant in First Remission,
Authors: Mahmoud Aljurf, Naeem A. Chaudhri, Fahed Almhareb, Claudia Ulrike Walter, Randa Nounou, Salem Khalil, Nasir Bakshi, Tarek Owaidah, Hazzaa Al Zahrani, Said Mohamed, Walid Rasheed, Fahad Alsharif, Maher Albitar
Journal: Blood (2011)
SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).
Authors: Jonathan Friedberg, Philip Cohen, Robert O. Kerr, K. Sue Robinson, Andres Forero-Torres, Richard van der Jagt, Elber Camacho, John Hainsworth, Brent Roeck, Pratik S. Multani
Journal: Blood (2004)
BMET-09CUMULATIVE INTRACRANIAL TUMOR VOLUME (CITV) ENHANCES THE PROGNOSTIC VALUE OF THE LUNG-SPECIFIC-GRADED PROGNOSTIC ASSESSMENT (GPA) MODEL
Authors: Logan Marcus, Deborah Marshall, Brandon McCutcheon, David Gonda, Steve Goetsch, Jona Hattangadi, Bob Carter, Masaki Yamamoto, Clark Chen
Journal: Neuro-Oncology (2015)

BACKGROUND: Management of patients afflicted with brain metastasis requires tailoring of therapeutic strategies based on survival expectations. As such, the development of prognostic indices is of critical importance in this patient population. OBJECTIVE: The purpose of this study was to determine whether the cumulative intracranial tumor volume (CITV) of brain metastasis augment the prognostic value of the lung-specific-Graded Prognostic Assessment (GPA) index. METHODS: Patient data was derived from 365 lung cancer patients with brain metastasis (BM) that were consecutively treated at the University of California, San Diego/San-Diego-Gamma-Knife-Center (UCSD/SDGKC). CITV was analyzed to determine the volume cutoff that maximized sensitivity and specificity for one-year survival on the ROC curve. Multivariate Cox proportional hazard modeling was performed, and overall survival was estimated by the Kaplan-Meier method risk stratifying by lung-specific-GPA with or without this optimal CITV. The prognostic value of these models (lung-specific GPA +/- CITV) was quantitatively compared using net reclassification improvement (NRI > 0) and integrated discrimination improvement (IDI). RESULTS: For the UCSD/SDGKC cohort, the CITV cutoff that had the greatest survival discrimination at one year was 4cm3. The addition of CITV to the lung-specific GPA indices significantly improved the prognostic value of lung-specific GPA (with NRI > 0 of 0.430 (CI = 0.228-0.629) and IDI of 0.029 (CI = 0.004-0.073)). These findings were validated in an independent cohort of 1,638 lung cancer BM patients that were SRS treated at the Katsuta Hospital Mito GammaHouse (KHMGH), Japan. CONCLUSION: In independent cohorts, the addition of CITV to lung-specific-GPA index significantly improved the prognostic value of this index.
The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago
Authors: Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A Godley, Justin Kline, John M Cunningham, James LaBelle, Michael R Bishop, Hongtao Liu
Journal: Blood (2014)
Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
Authors: Qiong J. Wang, Zhiya Yu, Ken-ichi Hanada, Krishna Patel, David Kleiner, Nicholas P. Restifo, James C. Yang
Journal: Clinical Cancer Research (2016)

Abstract Purpose: CD70 expression in normal tissues is restricted to activated lymphoid tissues. Targeting CD70 on CD70-expressing tumors could mediate “on-target, off-tumor” toxicity. This study was to evaluate the feasibility and safety of using anti-human CD70 CARs to treat cancer patients whose tumors express CD70. Experimental Design: Seven anti-human CD70 CARs with binding moieties from human CD27 combined with CD3-zeta and different costimulatory domains from CD28 and/or 41BB were constructed. In vitro functionality of these receptors was compared and in vivo treatment efficacy was evaluated in a xenograft mouse model. A homologous, all murine anti-CD70 CAR model was also used to assess treatment-related toxicities. Results: The CAR consisting of the extracellular binding portion of CD27 fused with 41BB and CD3-zeta (trCD27-41BB-zeta) conferred the highest IFNγ production against CD70-expressing tumors in vitro, and NSG mice bearing established CD70-expressing human tumors could be cured by human lymphocytes transduced with this CAR. In the murine CD27-CD3-zeta CAR model, significant reduction of established tumors and prolonged survival were achieved using CAR-transduced splenocytes in a dose-dependent manner. Host preirradiation enhanced treatment efficacy but increased treatment-related toxicities such as transient weight loss and hematopoetic suppression. The treatment did not appear to block adaptive host immune responses. Conclusions: Preclinical testing supports the safety and efficacy of a CD27-containing CAR targeting CD70-expressing tumors. Clin Cancer Res; 23(9); 2267–76. ©2016 AACR.
Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.
Authors: Ingo G.H. Schmidt-Wolf, Annika Juergens, Hendrik Pels, Axel Glasmacher, Holger Schulz, Andreas Engert, Michael Linnebank, Heinz Reichmann, Frank Kroschinsky, Marlies Vogt-Schaden, Gerlinde Egerer, Klaus Fliessbach, Uwe Schlegel
Journal: Blood (2006)
Resolving <i>TYK2</i> locus genotype-to-phenotype differences in autoimmunity
Authors: Calliope A. Dendrou, Adrian Cortes, Lydia Shipman, Hayley G. Evans, Kathrine E. Attfield, Luke Jostins, Thomas Barber, Gurman Kaur, Subita Balaram Kuttikkatte, Oliver A. Leach, Christiane Desel, Soren L. Faergeman, Jane Cheeseman, Matt J. Neville, Stephen Sawcer, Alastair Compston, Adam R. Johnson, Christine Everett, John I. Bell, Fredrik Karpe, Mark Ultsch, Charles Eigenbrot, Gil McVean, Lars Fugger
Journal: Science Translational Medicine (2016)

Resolving TYK2 locus genotype-to-phenotype differences reveals an immune signaling optimum that may be exploited therapeutically for treating autoimmune diseases.
Uncommon Presentations of Malignancies
Authors: Gregory D. Leonard, Upendra Hegde, John Butman, Elaine S. Jaffe, Wyndham H. Wilson
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.07.104 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12885820 Uncommon Presentations of Malignancies CASE 1. EXTRAOCULAR MUSCLE PALSIES IN SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA Gregory D. LeonardxGregory D. LeonardSearch for articles by this author , Upendra HegdexUpendra HegdeSearch for articles by this author , John ButmanxJohn ButmanSearch for articles by this author , Elaine S. JaffexElaine S. JaffeSearch for articles by this author , Wyndham H. WilsonxWyndham H. WilsonSearch for articles by this author Show More Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD https://doi.org/10.1200/JCO.2003.07.104 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data
Authors: Nanxin Li, Chelsey Yang, Liangyi Fan, Todor Totev, Annie Guerin, Lei Chen
Journal: Blood (2015)
A Novel DNA/RNA FISH X Inactivation Assay Reveals a Nonrandom, Ploidy-Dependent Acquisition of the Active and Inactive X Chromosomes in Childhood Hyperdiploid Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL).
Authors: Oskar A. Haas, Petra Zeitlhofer, Sabine Strehl, Michael Pfeilstoecker, Margit Koenig, Andreas Weinhaeusel
Journal: Blood (2004)